A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma

SGN-CD19B will be given to patients at increasing doses every 28 days (or on an alternative
dosing schedule of every 42 days).

Individual expansion cohorts of up to approximately 20 patients will be opened at dose levels
selected by the Safety Monitoring Committee based on the aggregate known safety and activity
data to further define the safety and antitumor activity in refractory and relapsed disease
subgroups.

Inclusion Criteria:

- Relapsed, refractory, or progressive disease following at least 2 prior systemic
therapies

- Measurable disease

- Eastern Cooperative Oncology Group status of 0 or 1

- Adequate baseline renal and hepatic function

Exclusion Criteria:

- Prior treatment with CD19 directed agents unless CD19 expression is confirmed after
completion of CD19-directed treatment

- Known HIV, active hepatitis B or active hepatitis C infection

- Prior allogeneic stem cell transplant

- Inadequate lung function

- Anticancer treatment within 4 weeks of study drug or 2 weeks if patient experienced
disease progression on prior treatment